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10 th NCI-EORTC SYMPOSIUM
ON NEW DRUGS IN CANCER THERAPY
Amsterdam, The Netherlands, June 16-19, 1998
This second announcement is to inform you on the scientific and social program of the 10th NCI-
EORTC Symposium on New Drugs in Cancer Therapy, to be held 16-19 June, 1998.
The series of NCI-EORTC Symposia is heading for the tenth edition in June 1998. Over the past 11
years, this series has built its reputation as one of the worlds best meetings and certainly as the most
dedicated meeting in the field of new anticancer therapies.
This meeting will cover actual developments in the field of anticancer drug research, both at the
preclinical and the clinical level. Many top speakers have already agreed to present a lecture on their
field of research at the symposium. The current announcement provides the provisional program.
The format remains largely unaltered compared to the previous meetings, although more workshops
will be held since these were highly appreciated at the previous symposium. In addition, the
Scientific Advisory Board will be reviewing the submitted abstracts very critically to even further
improve the quality of the poster presentations.
This will be the sixth consecutive meeting in this series to be organized by the EORTC New Drug
Development Office in Amsterdam. The increase to over 1,400 active participants on the occasion of
the 9th NCI-EORTC Symposium in March 1996 has demonstrated that the importance of this
meeting is now being recognized by many in academia, industry, and governmental agencies.
More than ever before it will be important to register as early as possible to prevent disappointment.
The maximum number of attendees that can be hosted is almost reached already. There will also be
more pressure on hotel accommodations this time due to the summer period, a popular time for
tourists to visit Amsterdam.
History of the series
The series of NCI-EORTC Symposia are a perfect reflection of the close collaboration between the
NCI (US National Cancer Institute) and the EORTC (European Organization for Research and
Treatment of Cancer) over the past decades. These two organizations are heavily involved in the
discovery of potential new anticancer agents and their subsequent development through the
various phases of preclinical and early clinical development.
A series of specialized symposia, held every 2-3 years since 1978, has been dedicated to this
theme. The first four of these symposia were held in Brussels, Belgium. In 1984, after Dr. Pinedo
had established the EORTC New Drug Development Office (NDDO) in Amsterdam, the symposium
moved to Amsterdam.
All subsequent symposia were organized by the NDDO, with Dr. Pinedo as the Symposium
President, starting with the 5th NCI-EORTC Symposium on New Drugs in Cancer Therapy in
October 1986.
Global forum
Since then, the symposium has seen a strong growth to over 1,400 participants from 35 countries at
the last meeting in March 1996. This growth has been achieved not only by increased participation
from European countries; there has been an even stronger increase in the number of participants
from other continents, notably North-America and the Far-East. Thus, approximately one-third of the
participants at the 9th symposium were non-European. So, the series has achieved a truly global
scale and provides an excellent forum to everyone involved in the research and development of
new anticancer agents which nowadays tends to occur in a worldwide setting.
Scope of the symposium
The symposium series aims to provide a forum for presentation and discussion of recent results in
the research and development of new anticancer agents in a broad sense, including compounds
from natural or synthetic origin, biological agents, immunological treatments, gene therapy, and
drugs designed to modify the action and/or the toxicity of existing anticancer agents. The
symposium covers both preclinical research and (early) clinical development of such drugs, including
methodologies employed in each of the research areas involved.
346The scientific program focuses on state-of-the-art presentations by top speakers, and is organized
according to the highest possible standards. The program is of interest to everyone with a scientific
interest in new anticancer drugs, e.g. in academic research institutes, the pharmaceutical industry,
and governmental or multinational research and regulatory agencies.
Scientific program
The scientific program will run from Tuesday, June 16, 1998, to Friday, June 19, 1998, late
afternoon. Elements of the program will be: the Opening Ceremony, including the Presidential
Address, the Michel Clavel Lecture, the NDDO Honorary Award Presentation, and several Keynote
Lectures; plenary lecture sessions in the morning and the afternoon; poster sessions; and daily
poster reviews as part of the afternoon plenary sessions. Due to positive reactions of participants of
the previous symposium, the number of workshops, allowing in-depth discussion on specific topics,
will be increased. Plenary sessions will be focused on particular areas of interest in preclinical and
clinical anticancer drug research like:
New mechanisms and cellular targets for anticancer agents
Anti-angiogenesis and anti-metastatic agents
New DNA-interactive agents (e.g. marine compounds)
Gene therapy
Novel delivery systems and prodrugs
Tubulin inhibitors: other mechanisms and combinations
Camptothecins: problems to overcome and future prospects
Apoptosis
Further topics will be announced in the final program.
Special attention will be given to aspects of translational research, linking preclinical (e.g. molecular
biology and genetics) data and clinical findings in a given area. The majority of presentations will be
given by invited speakers who are experts in the field. In addition, there will be a limited number of
slots for oral presentation of submitted papers which receive high ratings in the review process, and
the topics ef which fit in one of the sessions.
Poster sessions will be held on Wednesday, Thursday and Friday. Poster topics will cover all
areas within the scope of the symposium. Accepted posters will be displayed with ample time for
viewing and discussion during the extended lunch breaks. During the plenary sessions in the
afternoon an expert will present his/her review of posters displayed.
Topics for discussion in workshops, under supervision of a panel of experts, are"
Tumor vaccines
Combinatorial chemistry / diversity generation
Early clinical trials with radiosensitizers
New endpoints for Phase studies with new therapeutics
Pharmacokinetics and pharmacodynamics in drug development
Computer assisted drug development and molecular modelling
Detailed planning and additional topics for workshops will be announced in the final program.
Speakers and chairmen (provisional list)
J.H. Beijnen Amsterdam, Netherlands
Th.R. Boon Brussels, Belgium
M.C. Christian Bethesda, U.S.A.
S.T. Crooke Carlsbad, U.S.A.
J.A. Double Bradford, U.K.
I.J. Fidler Houston, U.S.A.
J. Folkman Boston, U.S.A.
M. Friedman Rockville, U.S.A
G. Giaccone Amsterdam, Netherlands
A. Hanauske MQnchen, Germany
A.L. Harris Oxford, U.K.
F. Hausheer San Antonio, U.S.A.
W.K. Hong Houston, U.S.A.
S.B. Horwitz New York, U.S.A
R. Jain Boston, U.S.A.
S.B. Kaye Glasgow, U.K.
S.J. Korsmeyer St-Louis, U.S.A.
A. Matter Basel, Switzerland
F. McCormick San Francisco, U.S.A.
C. Melief Leiden, Netherlands
J. Mendelsohn New York, U.S.A.
H. Newell Newcastle, U.K.
H.M. Pinedo Amsterdam, Netherlands
S. Rosenberg / M. Sznol Bethesda, U.S.A.
J. Roth Houston, U.S.A.
N. Saijo Tokyo, Japan
E.A. Sausville Bethesda, U.S.A.
T. Tursz Villejuif, France
J. Verweij Rotterdam, Netherlands
D.D. Von Hoff San Antonio, U.S.A.
R.E. Wittes Bethesda, U.S.A.
347Accreditation and certification
CME accreditation for the scientific program on behalf of medical oncologists participating in the
scientific program is already approved by the European Society of Medical Oncology (ESMO) and is
pending for the USA. Upon request, registered symposium participants will receive a certificate of
attendance at the end of the symposium.
Important dates
February 1, 1998: Deadline early registration
February 20, 1998: Deadline abstract submission
April 15, 1998" Deadline hotel reservation
May 1, 1998: Abstract notification
June 1, 1998: Deadline late registration
June 16-19, 1998: 10th NCIoEORTC Symposium on New Drugs in Cancer Therapy
More information for instance on abstract sumission or registration can be obtained from
Dr. M. R. L. Krul
Conference Coordinator
EORTC New Drus Development Office
P. O. Box 7057
NL- 1007 MB Amsterdam, The Netherlands
Phone: + 31 20 444 2768
Fax: + 31 20 444 2699
e-mail" krul@euronet.nl
Additional information can also be found on the home page oif the Symposium at
http://www.eortc.be/seminar/newdrugs
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